DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Pfizer's - 2 Pfizer hasn't - 2 Wall - 1 Seagen - 1 Chris Boshoff - 1 Boshoff - 1 David Ryder - 1 Trung Huynh - 1
Top related locs:
U.S Covid Bothell , Washington biologics China Eagle Rock , California New York
Top related orgs:
Pfizer - 2 CNBC - 2 Nurphoto - 1 Getty - 1 Astellas Pharma - 1 Guggenheim - 1 Bloomberg - 1 UBS - 1

Search resuls for: "Pfizer hasn't"


2 mentions found


☆ Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
  + stars: | 2024-03-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +13 min
Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. That $43 billion Seagen acquisition doubled Pfizer's oncology drug pipeline to 60 different experimental programs. Some analysts noted that it might take a few years for some of Pfizer's cancer drugs in mid-stage development to show pivotal clinical trial data and become less risky. Revenue from the blockbuster breast cancer drug Ibrance and prostate cancer treatment Xtandi, which Pfizer shares with Astellas Pharma, has declined over the past year. They are among the most expensive prescription drugs in the U.S. Before the Seagen deal, 94% of Pfizer's cancer products were small-molecule drugs.
Persons: Wall, Seagen, Chris Boshoff, Boshoff, David Ryder, Trung Huynh, Joe Biden's, Chris Schott, Suneet Varma, RemeGe, Merck, Padcev, Guggenheim, Pfizer's, Pfizer hasn't, Dr, Mikael Dolsten, Irfan Khan Organizations: Nurphoto, Getty, Pfizer, Astellas Pharma, Guggenheim, Bloomberg, UBS, Medicare, Drug Administration, FDA, ADC, JPMorgan, Drugs, CNBC, CVS Pharmacy, Los Angeles Times Locations: Covid, Bothell , Washington, U.S, biologics, China, Eagle Rock , California
☆ Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
  + stars: | 2023-06-21 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Pfizer 's vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer's clinical trial on more than 34,000 older adults over two RSV seasons, or 24 months. The vaccine was roughly 49% effective against the same condition with two or more symptoms after 18 months, according to Pfizer. Anderson said studies are ongoing, and so is research evaluating the shot's efficacy in older adults with weak immune systems. RSV kills 6,000 to 10,000 older adults and hospitalizes 60,000 to 160,000 of them every year, according to the CDC.
Persons: Pfizer's, It's, Annaliesa Anderson, Anderson, Pfizer hasn't Organizations: Pfizer, Northern, That's, Centers for Disease Control, and Drug Administration, GlaxoSmithKline, CNBC, CDC Locations: New York, U.S
0 next >>
Total: 2